

Xintela and NorthX Biologics sign collaboration framework agreement

Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among other things.

“This is a very exciting opportunity for us. Xintela has developed the superior stem cell product XSTEM, which is now in clinical development, and has strong competence in process development and GMP manufacturing of stem cells and other ATMPs. Together with NorthX Biologics and their manufacturing capacity we can further expand and also broaden our ATMP business”, says Evy Lundgren-Åkerlund, CEO of Xintela.

“This collaboration is another step in the right direction towards becoming a leading solutions provider in the cell and gene therapy space, adding to the solid competence NorthX already gained from +30 years of advanced biological GMP manufacturing. I am excited to work with Xintela and look forward to our relationship going forward”, says Helena Strigård, CEO of NorthX Biologics.

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

About NorthX Biologics

NorthX Biologics provides process development and manufacturing services with expertise in plasmids, proteins and other advanced biologics. NorthX Biologics is headquartered in Matfors, Central Sweden, and the team has been manufacturing biologics to GMP standards since 1992. In 2021 NorthX was designated a national innovation hub for advanced therapies and vaccines. NorthX has the ambition to become an internationally leading cell and gene therapy manufacturer and partner for innovative drug development companies. For more information see www.nxbio.com.

Attachments

[Xintela and NorthX Biologics sign collaboration framework agreement](#)